

Review began 11/19/2024 Review ended 11/25/2024 Published 11/27/2024

© Copyright 2024

Metwally et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI: 10.7759/cureus.74558

Calciphylaxis in a Patient on Hemodialysis: A Case Report

Yahia Metwally ¹, Hashim Abbas ¹, Vishnu Jeyalan ¹, Amjad Khanfar ²

 $1.\ Nephrology, Manchester\ University\ NHS\ Foundation\ Trust,\ Manchester,\ GBR\ 2.\ Cardiology,\ Manchester\ University\ NHS\ Foundation\ Trust,\ Manchester,\ GBR$

Corresponding author: Yahia Metwally, yah.metwally@gmail.com

Abstract

Calciphylaxis is a rare but life-threatening complication of end-stage renal disease (ESRD), most often seen in patients undergoing hemodialysis. This condition is driven by calcium deposition in small blood vessels, leading to restricted blood flow, tissue ischemia, and often severe pain. While calciphylaxis typically affects areas with increased adiposity, such as the abdomen and proximal extremities, it can manifest on any skin surface, including rare sites like the genital region. Managing calciphylaxis is particularly challenging due to its rapid progression and limited treatment options. We report the case of a 53-year-old man with ESRD caused by long-standing diabetes, who developed painful necrotic lesions on the glans penis. Despite early diagnosis and treatment with sodium thiosulfate, his condition rapidly worsened. This case highlights the devastating progression of penile calciphylaxis and the complexities of managing such a rare presentation.

Categories: Radiology, Urology, Nephrology

Keywords: calciphylaxis, ckd, end stage renal disease (esrd), hemodialysis, penile calciphylaxis, serious complication of hemodialysis, sodium thiosulfate, uremic calciphylaxis, warfarin-induced calciphyalxis

Introduction

Chronic kidney disease (CKD) affects approximately 3.5 million individuals in the United Kingdom, with uncontrolled diabetes and hypertension being the primary etiologies. Among these, over 68,000 patients have progressed to kidney failure (stage 5 CKD), necessitating renal replacement therapies such as dialysis or transplantation. CKD significantly contributes to mortality, accounting for an estimated 40,000 to 45,000 deaths annually in the UK. Notably, individuals from Black, Asian, and minority ethnic groups are at a fivefold increased risk of developing CKD compared to other populations [1,2].

Calciphylaxis, also known as calcific uremic arteriolopathy, is a rare but devastating complication of CKD, particularly in patients with ESRD on hemodialysis. This condition involves calcification of small and medium-sized arterioles, leading to ischemic necrosis of the skin and subcutaneous tissues. While calciphylaxis commonly affects areas with abundant adipose tissue, such as the thighs and abdomen, penile involvement is exceedingly rare, accounting for approximately 6% of cases. Penile calciphylaxis carries a particularly poor prognosis, with mortality rates estimated at 50% within three months and 62.5% at six months [1].

The pathogenesis of calciphylaxis is multifactorial, involving disturbances in calcium-phosphate metabolism, hyperparathyroidism, and vascular calcification. Risk factors include diabetes mellitus, obesity, hyperphosphatemia, hypoalbuminemia, and the use of medications such as warfarin. Clinical presentation typically includes painful, violaceous skin lesions that may progress to necrotic ulcers [2,3]. Diagnosis is primarily clinical and management is usually challenging and often requires a multidisciplinary approach.

In this report, we present a case of penile calciphylaxis in a patient with ESRD secondary to diabetes mellitus, highlighting the clinical course, diagnostic challenges, and therapeutic interventions undertaken. This case underscores the aggressive nature of penile calciphylaxis and the need for heightened awareness and prompt management of this rare condition.

Case Presentation

A 69-year-old man with end-stage renal disease (ESRD) and atrial fibrillation presented to the dialysis unit with severe penile pain and lesions. Notably, he had visited the Emergency Department weeks earlier with similar symptoms and was evaluated by the urology team, but calciphylaxis was not initially considered as a potential diagnosis.

On examination, painful necrotic lesions were observed on the penis, raising significant concern. A follow-up assessment a week later revealed rapid and alarming progression of the lesions (Figures 1-2), prompting the clinical team to strongly consider calciphylaxis. Treatment was initiated immediately.





FIGURE 1: Painful penile lesions



FIGURE 2: Painful and very tender penile lesions (Calciphylaxis).

The patient was taking warfarin for atrial fibrillation, a medication known to be associated with an increased risk of calciphylaxis. Given this, warfarin was promptly discontinued. This case highlights the importance of developing a risk assessment protocol for ESRD patients before starting warfarin therapy, as its use can inadvertently exacerbate already fragile vascular conditions.

To address the calciphylaxis, the patient was started on sodium thiosulfate during his dialysis sessions. Sodium thiosulfate is thought to work through a dual mechanism: chelating calcium ions to form a more soluble compound, calcium thiosulfate, which is easier for the body to clear, and acting as an antioxidant to reduce oxidative damage. This therapy is often considered first-line for calciphylaxis. Alternative treatments such as hyperbaric oxygen therapy, with or without surgical debridement of necrotic tissue, have also been reported in the literature, along with emerging options like apheresis and tissue plasminogen activators. However, these were not pursued in this case.

Despite receiving several sessions of sodium thiosulfate alongside dialysis, the patient's condition continued




to decline. Sadly, he passed away three weeks after his diagnosis. This tragic outcome highlights the significant cardiovascular burden and advanced vessel disease that often accompany this rare and devastating condition.

Discussion

Penile calciphylaxis is a rare and severe manifestation of calcific uremic arteriolopathy, primarily affecting patients with ESRD undergoing hemodialysis [4,5]. It is characterized by calcification of small and medium-sized arterioles, resulting in ischemia and necrosis of penile tissue [6-8]. The prognosis for calciphylaxis is extremely poor, with mortality rates exceeding 50% within three months of diagnosis [1,8,9].

The pathogenesis of calciphylaxis is multifactorial, involving disturbances in calcium-phosphate metabolism, secondary hyperparathyroidism, and extensive vascular calcification. Known risk factors include diabetes mellitus, obesity, hyperphosphatemia, hypoalbuminemia, and the use of medications such as warfarin [2,6,7,10,11]. In the presented case, the patient's ESRD and warfarin therapy for atrial fibrillation likely contributed to the development of penile calciphylaxis. Images obtained for this patient over a three-year period demonstrated significant progression of vascular calcifications (Figures *3-6*), underscoring the profound vascular burden associated with this disease.






FIGURE 3: Computed Tomography (CT) abdomen and pelvis following intravenous contrast administration in portal venous phase.

Images were obtained with a time difference of 3 years. On baseline examination (Right image), there was moderate diffuse calcified atherosclerosis affecting the abdominal aorta and main abdominal and pelvic branches (red arrow). Follow-up examination (left image) showed significant interval worsening especially involving splanchnic and mesenteric vasculature (blue arrow), bilateral iliac axis and deep pelvic branches.








FIGURE 4: Coronal maximal intensity projection reformatted computed tomography (CT) and anterior projection 3-dimensional volume rendering.

Images were obtained with a time difference of 3 years. On baseline examination (right image), there was moderate diffuse calcified atherosclerosis affecting the abdominal aorta and main abdominal and pelvic branches (red arrows). Follow-up examination (left image) showed significant interval worsening especially involving splanchnic and mesenteric vasculature, bilateral iliac axis and deep pelvic branches (blue arrows).







FIGURE 5: The coronal maximum intensity projection reformatted Computed Tomography (CT) images of the pelvis demonstrate significant interval progression of vascular calcifications over a three-year period.

The image on the right represents the baseline examination, showing calcifications involving the bilateral external iliac, femoral (red arrows) and external pudendal arteries. In contrast, the image on the left illustrates marked worsening of calcifications in the bilateral external iliac, femoral (blue arrows), and external pudendal (yellow arrows) arteries; indicative of progressive vascular burden associated with the patient's condition.








FIGURE 6: The axial maximum intensity projection reformatted computed tomography (CT) images reveal a significant interval worsening of calcifications in the penile arteries.

The image on the left shows more pronounced calcifications in both the cavernosal and dorsal arteries of the penis (blue arrows), indicating disease progression when compared to the baseline examination on the right for the same arteries (red arrows).

Patients with penile calciphylaxis typically present with painful, violaceous skin lesions that may progress to necrotic ulcers [2,7,9,11]. Diagnosis is primarily clinical but can be supported by imaging studies that reveal vascular calcifications and, in some cases, skin biopsy to confirm the diagnosis [7,8,10,11]. In this case, the initial presentation of penile pain and lesions, followed by rapid necrotic progression, aligns with the typical clinical features of penile calciphylaxis.

Management of calciphylaxis is highly challenging and requires a multidisciplinary approach. Treatment strategies focus on wound care, pain management, discontinuation of offending agents such as warfarin [6,7,9], correction of metabolic abnormalities, and the use of therapeutic agents like sodium thiosulfate [6,7,10,12]. In specific cases, surgical debridement of necrotic tissue may be necessary [2,3]. For this patient, discontinuation of warfarin and initiation of sodium thiosulfate therapy were appropriate steps. However, despite these interventions, the condition progressed rapidly, reflecting the aggressive nature of penile calciphylaxis and the difficulties associated with its management.

The prognosis for penile calciphylaxis remains grim, with mortality rates estimated at 50% within three months and 62.5% at six months [1,8,9,12]. This patient's rapid decline and death only three weeks after diagnosis highlight the devastating course of this rare disease. These findings stress the importance of early recognition, aggressive management, and the need for further research into more effective treatment strategies for calciphylaxis.

Conclusions

This case addresses several important lessons in the management of calciphylaxis. First, it highlights the need for a robust risk assessment tool before initiating warfarin therapy in patients with ESRD. Given the well-documented association between warfarin and calciphylaxis, clinicians must carefully balance the benefits of anticoagulation with the risk of this life-threatening complication. Second, the importance of early recognition cannot be overstated. Although calciphylaxis is a rare condition, its consequences when unrecognized can be devastating. Clinicians must maintain a high index of suspicion for calciphylaxis when managing patients with kidney disease, including those with acute kidney injury, who present with new and painful skin lesions. A multidisciplinary diagnostic approach-including dermatologic evaluation, histopathological analysis, and radiographic tools-may be necessary to achieve a timely and accurate diagnosis. Finally, this case highlights the profound vascular burden associated with calciphylaxis, which reflects the severity of systemic disease when symptoms appear. Addressing this burden requires a multidisciplinary approach to management, including metabolic control, pain relief, wound care, and adjunctive therapies such as sodium thiosulfate. The integration of these strategies is crucial for optimizing outcomes in this challenging and often fatal condition.

Additional Information



Author Contributions

All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.

Concept and design: Yahia Metwally, Hashim Abbas, Vishnu Jeyalan, Amjad Khanfar

Acquisition, analysis, or interpretation of data: Yahia Metwally, Hashim Abbas, Vishnu Jeyalan, Amjad Khanfar

Drafting of the manuscript: Yahia Metwally, Hashim Abbas, Vishnu Jeyalan, Amjad Khanfar

Critical review of the manuscript for important intellectual content: Yahia Metwally, Hashim Abbas, Vishnu Jeyalan, Amjad Khanfar

Supervision: Hashim Abbas, Vishnu Jeyalan

Disclosures

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

- Gabel C, Chakrala T, Shah R, et al.: Penile calciphylaxis: A retrospective case-control study. J Am Acad Dermatol. 2021, 85:1209-17. 10.1016/j.jaad.2020.05.042
- Wipattanakitcharoen A, Takkavatakarn K, Susantitaphong P: Risk factors, treatment modalities, and clinical outcomes of penile calciphylaxis: Systematic review. World J Urol. 2023, 41:2959-66. 10.1007/s00345-023-04611.0
- O'Beirn E, Muheilan M, Casey R: Penile calciphylaxis—a complicated case managed with circumcision and glansectomy. J Surg Case Rep. 2022, 2022:rjab590. 10.1093/jscr/rjab590
- Grandez-Urbina JA, Corrales-Acosta E, Tejeda-Mariaca JE, Pichardo-Rodriguez R, Garcia-Perdomo H: Case Report: Penile necrosis associated to paraphimosis with calciphylaxis due to terminal chronic kidney disease. F1000Res. 2019, 8:1133. 10.12688/f1000research.18834.1
- Budisavljevic MN, Cheek D, Ploth DW: Calciphylaxis in chronic renal failure. J Am Soc Nephrol. 1996, 7:978-82. 10.1681/ASN.V77978
- Patecki M, Lehmann G, Bräsen JH, et al.: A case report of severe calciphylaxis suggested approach for diagnosis and treatment. BMC Nephrol. 2017, 18:137. 10.1186/s12882-017-0556-z
- Turek M, Stępniewska J, Różański J: The multifactorial pathogenesis of calciphylaxis: A case report . Am J Case Rep. 2021, 22:e930026. 10.12659/AJCR.930026
- 8. Hall DJ, Gentile LF, Duckworth LV, Shaw CM, Singhal D, Spiguel LR: Calciphylaxis of the breast: A case report and literature review. Breast J. 2016, 22:568-72. 10.1111/tbj.12632
- Yalin AS, Altiparmak MR, Trabulus S, Yalin SF, Yalin GY, Melikoglu M: Calciphylaxis: A report of six cases and review of literature. Ren Fail. 2013, 35:163-9. 10.3109/0886022X.2012.741426
- Karpman E, Das S, Kurzrock EA: Penile calciphylaxis: Analysis of risk factors and mortality. J Urol. 2003, 169:2206-9. 10.1097/01.ju.0000064334.85656.a1
- Gallo Marin B, Aghagoli G, Hu SL, Massoud CM, Robinson-Bostom L: Calciphylaxis and kidney disease: A review. Am J Kidney Dis. 2023, 81:232-9. 10.1053/j.ajkd.2022.06.011
- Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P: Treatment of calciphylaxis in CKD: A systematic review and meta-analysis . Kidney Int Rep. 2019, 4:231-44. 10.1016/j.ekir.2018.10.002